SOLARA.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 13:00):

Stats
Šios dienos apimtis	200 303
Vidutinė apimtis	549 880
Rinkos kapitalizacija	19.52B
EPS	INR0 ( 2024-02-14 )
Kita pelno data	( INR0 ) 2024-05-09
Last Dividend	INR3.00 ( 2021-08-18 )
Next Dividend	INR0 ( N/A )
P/E	-6.33
ATR14	INR1.013 (0.19%)

Tūris Koreliacija

Ilgas: -0.29 (neutral)

Trumpas: 0.41 (neutral)

Signal:(43.412) Neutral

Solara Active Pharma Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Solara Active Pharma Koreliacija - Valiuta/Žaliavos

-0.45
( neutral )

0.14
( neutral )

0.53
( weak )

-0.37
( neutral )

-0.04
( neutral )

0.00
( neutral )

Solara Active Pharma Finansinės ataskaitos

Annual	2022
Pajamos:	INR14.44B
Bruto pelnas:	INR6.55B (45.37 %)
EPS:	INR-6.16

FY	2022
Pajamos:	INR14.44B
Bruto pelnas:	INR6.55B (45.37 %)
EPS:	INR-6.16

FY	2022
Pajamos:	INR12.31B
Bruto pelnas:	INR5.33B (43.29 %)
EPS:	INR-16.22

FY	2021
Pajamos:	INR16.17B
Bruto pelnas:	INR8.47B (52.40 %)
EPS:	INR69.00

Financial Reports:

No articles found.

Solara Active Pharma Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Solara Active Pharma Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 1.727 - No dividend growth expected in the near future

Information

First Dividend	INR5.00	2019-08-06
Last Dividend	INR3.00	2021-08-18
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	4	--
Total Paid Out	INR14.00	--
Avg. Dividend % Per Year	0.13%	--
Score	0.73	--
Div. Sustainability Score	0
Div.Growth Potential Score	1.727
Div. Directional Score	0.447	--

Next Divdend (Est)
(2024-12-02)

INR0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

0.73

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2019	INR5.00	1.62%
2020	INR6.00	1.41%
2021	INR3.00	0.25%
2022	INR0	0.00%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
TINPLATE.NS	Dividend Junior	2023-08-11	Annually	19	0.72%
PDMJEPAPER.NS	Dividend Junior	2023-08-03	Annually	9	0.65%
J&KBANK.NS	Dividend Junior	2023-08-17	Sporadic	22	0.47%
DATAMATICS.NS	Dividend Junior	2023-09-22	Annually	21	0.49%
SHYAMMETL.NS	Dividend Junior	2023-06-05	Semi-Annually	4	0.70%
MAXHEALTH.NS	Dividend Junior	2023-09-08	Insufficient data to determine frequency	2	0.07%
GSPL.NS	Dividend Junior	2023-09-01	Annually	19	0.81%
BANKINDIA.NS	Dividend Junior	2023-06-20	Sporadic	23	1.34%
PRAJIND.NS	Dividend Junior	2023-07-19	Annually	22	0.83%
KABRAEXTRU.NS	Dividend Junior	2023-07-13	Annually	23	0.83%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.219	1.500	-4.38	-6.57	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	-0.276	1.500	-4.18	-6.27	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	-1.607	1.000	-1.706	-1.706	[3 - 30]
operatingCashFlowPerShareTTM	43.40	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	43.40	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.342	1.000	7.64	7.64	[0.2 - 0.8]
operatingProfitMarginTTM	-0.110	1.000	-4.20	-4.20	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				-0.832

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-6.33	1.000	-0.741	0	[1 - 100]
returnOnEquityTTM	-0.276	2.50	-2.69	-6.27	[0.1 - 1.5]
freeCashFlowPerShareTTM	43.40	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	43.40	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.111	1.000	9.72	0	[0.1 - 0.5]
Total Score				1.727

Solara Active Pharma

Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India. The company offers APIs for anesthetics, anthelmintic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-viral, antibiotic, anticoagulant, anticonvulsant, antidepressant, antiemetic, antiepileptic, antifungal, antigout agent, antihistamine, antihyperlipoproteinemic, antimalarial, antimycotic, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antitussive, antiulcerative, anxiolytic, bile acid analogue, calcimimetic agent, cardiovascular agent, central nervous system agent, chronic alcoholism, chronic kidney disease, dopamine receptor antagonist, folate analog, hyperkalaemia, immunosuppressant, lipid regulating agent, loop diuretic, muscarinic agonist, neuromuscular, OAB treatment, phenylalanine reducer, recovery of stroke, tardive dyskinesia, treatment of glaucoma and hyperphosphatemia, tropical anti-infective, and type-II diabetes therapeutic categories. It also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical services, impurity synthesis, and regulatory support. In addition, the company exports its products. It operates in the Asia Pacific, Europe, North America, South America, and internationally. The company was formerly known as SSL Pharma Sciences Limited and changed its name to Solara Active Pharma Sciences Limited in March 2017. Solara Active Pharma Sciences Limited was incorporated in 2017 and is based in Chennai, India.